NMPA Approval

Ramucirumab Injection

Approval Number

国药准字SJ20220011

Registration Date

March 16, 2022

Drug Information

Generic Name

雷莫西尤单抗注射液

Trade Name

希冉择

Dosage Form

注射剂

Strength

500mg/50mL

Drug Type

生物制品

Registration Date

March 16, 2022

Expiry Date

March 15, 2027

Company Address

Lilly Corporate Center, Indianapolis, IN 46285 United States of America

Company Address

Lilly Corporate Center, Indianapolis, IN 46285 United States of America

Empowering clinical research with data-driven insights and AI-powered tools.